Tonix Pharmaceuticals has announced that their COVID-19 vaccine, TNX-1800, has been selected for testing in Project Next Gen. This initiative is a joint project managed by the White House and the Department of Health and Human Services (HHS), National Institutes of Health (NIH), and National Institute of Allergy and Infectious Diseases (NIAID).
The TNX-1800 vaccine uses a live virus platform that offers a unique way of stimulating the immune system. This technology provides longer-lasting and potentially transmission-blocking immunity compared to mRNA vaccines. The selection of TNX-1800 for this program is a result of Tonix Pharmaceuticals’ almost ten years of dedication to vaccine development. Additionally, the technology platform can be adapted to protect against other infectious diseases, such as monkeypox, smallpox, and tuberculosis.
The choice of TNX-1800 highlights the importance of vaccine platforms in addressing various infectious threats. Tonix’s approach offers the promise of more durable immunity and potential transmission prevention, potentially revolutionizing our approach to infectious disease control. Furthermore, the adaptability of this platform makes it a valuable tool for future vaccine strategies, making it a versatile solution for future pandemics.
For more information about Tonix Pharmaceuticals and their COVID-19 vaccine program, please contact Proactive Studio at +1 347-449-0879 or email them at email@example.com.